Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
Med (New York, N.Y.)|March 12, 2024
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosisAnne Knisely, Emily Hinchcliff, Bryan Fellman, et al.
Journal for Immunotherapy of Cancer|July 26, 2022
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signalingSamantha M Fix, Marie-Andrée Forget, Donastas Sakellariou-Thompson, et al.
Cancer Research|July 31, 2019
Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian CancerStephen Shang, Jiekun Yang, Amir A Jazaeri, et al.
International Journal of Molecular Sciences|August 14, 2025
Feasibility of Manufacturing and Antitumor Activity of TIL for Advanced Endometrial CancersYongliang Zhang, Kathleen N Moore, Amir A Jazaeri, et al.
Cancers|July 27, 2022
Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian CancerLi Zhao, Sara Corvigno, Shaolin Ma, et al.
Cancer|March 17, 2023
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancerKatherine I Foster, Kenna R M Shaw, Jeff Jin, et al.
Oncotarget|September 2, 2015
Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumorsEusebio S Pires, Ryan S D'Souza, Marisa A Needham, et al.
Journal of Cutaneous Pathology|September 14, 2017
Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patientsMichael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, et al.
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Journal of Surgical Oncology|May 31, 2021
Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibilityErin M Corsini, Kyle G Mitchell, Nicolas Zhou, et al.
Pageof 11